4 studies found for:    gog-0186K
Show Display Options
Rank Status Study
1 Active, not recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis
2 Active, not recruiting Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Pazopanib Hydrochloride;   Other: Placebo;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis
3 Active, not recruiting Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Fosbretabulin Tromethamine;   Other: Laboratory Biomarker Analysis
4 Active, not recruiting Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab;   Drug: everolimus;   Other: placebo

Indicates status has not been verified in more than two years